|
gptkbp:instanceOf
|
gptkb:drug
angiotensin II receptor blocker
|
|
gptkbp:approvalYear
|
1996
|
|
gptkbp:approvedBy
|
gptkb:Switzerland
|
|
gptkbp:ATCCode
|
C09CA03
|
|
gptkbp:bioavailability
|
25%
|
|
gptkbp:brand
|
gptkb:Diovan
|
|
gptkbp:CASNumber
|
137862-53-4
|
|
gptkbp:combines
|
gptkb:amlodipine
gptkb:hydrochlorothiazide
gptkb:sacubitril
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
bilateral renal artery stenosis
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
antihypertensive
|
|
gptkbp:eliminationHalfLife
|
6 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C24H29N5O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Valsartan
|
|
gptkbp:KEGGID
|
D02361
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
blocks angiotensin II type 1 receptor
|
|
gptkbp:MedlinePlusID
|
a697015
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
435.52 g/mol
|
|
gptkbp:patentExpired
|
2012
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:prescribes
|
adults
children over 6 years
|
|
gptkbp:proteinBinding
|
94–97%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521
DB00177
54829
60846
|
|
gptkbp:routeOfAdministration
|
oral
by mouth
|
|
gptkbp:sideEffect
|
dizziness
fatigue
headache
renal impairment
hyperkalemia
|
|
gptkbp:UNII
|
57T7FGF7MW
|
|
gptkbp:usedFor
|
heart failure
hypertension
post-myocardial infarction
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Viatris
|
|
gptkbp:bfsLayer
|
8
|